Perfluorinated compounds are related to breast cancer risk in greenlandic inuit: A case control study

Bonefeld-Jorgensen, Eva C; Long, Manhai; Bossi, Rossana; Ayotte, Pierre; Asmund, Gert; Krüger, Tanja; Ghisari, Mandana; Mulvad, Gert; Kern, Peder; Nzulumiki, Peter; Dewailly, Eric

doi:10.1186/1476-069X-10-88

Environmental Health

Table 4 Odds ratios of breast cancer and 95% confidence intervals associated with PFCs and POPs among breast cancer patients and controls

From: Perfluorinated compounds are related to breast cancer risk in greenlandic inuit: A case control study

	Raw¹			Raw²			Adjusted³
variables	n	OR	p	n	OR	p	n	OR	p
	(controls/cases)	(95% CI)		(controls/cases)	(95% CI)		(controls/cases)	(95% CI)
POPs
PFOS (ng/ml)	98/31	1.01 (1.003; 1.02)	0.02	69/9	1.01(0.99; 1.03)	0.23	69/9	1.03 (1.001; 1.07)	0.05
PFOA(ng/ml)	98/31	1.07 (0.88; 1.31)	0.50	69/7	0.94 (0.05; 1.38)	0.76	69/7	1.20 (0.77; 1.88)	0.43
sumPFSA(ng/ml)	98/31	1.013 (1.002;1.023)	0.02	69/15	1.01(0.99; 1.02)	0.37	69/15	1.03(1.00; 1.05)	0.02
sumPFCA(ng/ml)	98/31	1.05 (0.99; 1.11)	0.14	69/12	1.01(0.93; 1.10)	0.82	69/12	1.07(0.96; 1.18)	0.23
Sum PCB (μg/kg lipid)*	115/30	1.00(1.00; 1.00)	0.35	115/30	1.00(1.00; 1.00)	0.35	115/30	1.00(1.00; 1.00)	0.35
Sum OCP (μg/kg lipid)*	115/30	1.00(1.00; 1.00)	0.13	115/30	1.00(1.00; 1.00)	0.13	115/30	1.00(1.00; 1.00)	0.13
Sum PCB+sum OCP (μg/kg lipid)*	115/30	1.00(1.00; 1.00)	0.19	115/30	1.00(1.00; 1.00)	0.19	115/30	1.00(1.00; 1.00)	0.19
Sum PCB + sum OCP + sum PFSA + sum PFCA(ng/ml)	115/31	1.01(1.001; 1.014)	0.03	85/11	1.01(0.99; 1.02)	0.37	85/11	1.02(1.01; 1.04)	0.01
Metals
Se (μg/kg)	115/30	1.0 (0.998; 1.001)	0.61	96/27	0.99(0.998; 1.001)	0.51	96/27	0.999(0.99; 1.001)	0.47
Xenobiotic induced transactivities
XER(RLU/μg protein)	110/31	0.41(0.02; 7.50)	0.55	81/7	0.90 (0.001;663.8)	0.78	81/7	1.17(0.001; 1936)	0.97
XER < 1	23/8	28.9 (0.00; 301126)	0.48	11/3	9.49 (0.00;8.34e8)	0.81	11/3	0.00 (0.00; ∞)	0.65
XER > 1	87/23	0.09 (0.00; 23.8)	0.40	70/6	0.66(0.00; 9476)	0.93	70/6	1.85 (0.00; 79767)	0.91
XERcomp (RLU/μg protein)	110/31	2.15 (0.09; 53.77)	0.64	81/7	0.53(0.00; 18980)	0.91	81/7	0.22(0.00; 1166)	0.73
XERcomp <1	40/9	0.67 (0.00.00; 436)	0.90	20/1	0 (0.00; ∞)	0.995	20/1	0.00 (0.000; ∞)	0.99
XERcomp >1	70/22	0.60 (0.00; 1142)	0.89	61/6	0.06(0.00; 56092)	0.67	61/6	0.00(0.000; 111.6)	0.12
XAR(RLU/μg protein)	58/27	8.52 (1.55; 46.78)	0.01	49/11	28.5 (1.79; 452.6)	0.02	49/11	44.14(1.99; 975.7)	0.02
XARcomp(RLU/μg protein)	58/27	0.70(0.09; 5.31)	0.73	47/7	4.27 (0.17; 106.7)	0.38	47/7	5.04(0.20; 130.3)	0.33
AhR-TEQ(pg/g lipid)	113/29	0.99(0.99; 1.001)	0.09	83/6	1.003(0.98; 1.02)	0.77	83/6	1.01(0.98; 1.029)	0.58

Raw¹: unadjusted data of full number of samples. Raw²: unadjusted data for the subset having all the corresponding adjustment variables (age, BMI, pregnancy, cotinine, breastfeeding, menopausal status), Adjusted³: fully adjusted data for the corresponding confounders. OR: odds ratio. CI: confidence interval. For sum PFSA, sum PFCA, sum PCB, sum OCP see legend of Table 2. For XER, XERcomp, XAR, XARcomp and TEQ see legend of Table 3. *: not adjusted since no confounder was identified.

Back to article page

ISSN: 1476-069X

Contact us

General enquiries: journalsubmissions@springernature.com